7.3 Staff Investigators Within the UCSF Helen Diller Family Comprehensive Cancer Center are investigators who perform key roles in the activities of the Center, but are not specifically represented in our senior leader or programmatic line-up. Our Staff Investigators make sure that we, as a Center, are at the cutting edge of specific research areas that we believe will be important growth areas and opportunities in the future. Staff Investigators attend our quarterly off-site retreats, and report to the other members ofthe Center's leadership on new developments in these areas. In this application, we propose five of these individuals for funding: Celia Kaplan, Ph.D., Coordinator, Inreach Dr. Kaplan's research is in the field of health disparities and cancer prevention and control, as well as in conducting epidemiologic, health services, and communication research, with an emphasis on cancer care disparities. Her work has focused on assessing individual, community, and system factors associated with health access, and in factors affecting participation in clinical trials among patients, physicians, and community organizations. This expertise has led to the work she initiated, and will pursue as Staff Investigator. Dr. Kaplan partnered with Dr. Eric Small, Deputy Director and Associate Director of Clinical Sciences and of the Investigational Trials Resource (ITR), to evaluate the patterns of accrual to clinical trials at the Center. Overall accrual of minority and underserved populations (relative to the distribution of new cases seen at the Center, and relative to several catchment areas), and the relative contributions of outreach and inreach were evaluated. The results from this work led to the decision to specifically build an inreach effort in the Center. Dr. Kaplan will direct this initiative as part of her role as a Staff Investigator. Dr. Kaplan has established a center-wide initiative entitled,

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA082103-14
Application #
8388395
Study Section
Subcommittee G - Education (NCI)
Project Start
1999-08-05
Project End
2017-05-31
Budget Start
2012-09-19
Budget End
2013-05-31
Support Year
14
Fiscal Year
2012
Total Cost
$35,793
Indirect Cost
$12,934
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744

Showing the most recent 10 out of 192 publications